Hypersensitivity and Cardiovascular Risks Related to Allopurinol and Febuxostat Therapy in Asians: A Population‐Based Cohort Study and Meta‐Analysis
- 28 January 2019
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 106 (2) , 391-401
Abstract
The safety of newer xanthine oxidase inhibitor febuxostat compared to allopurinol remains unclear. To compare the risks of allopurinol hypersensitivity and febuxostat hypersensitivity and cardiovascular diseases (CVDs) in Asians, we conducted a population‐based cohort study enrolling patients receiving allopurinol or febuxostat from Chang Gung Memorial Hospital Health System across Taiwan during 2012–2016 and further performed a meta‐analysis incorporating two recent studies. Among the 61,539 users, a corresponding 12,007 and 5,680 patients were identified as new users. The overall incidence of febuxostat hypersensitivity was significantly lower than allopurinol hypersensitivity (0.2 vs. 2.7 per 1,000 new users; P < 0.001). There were 33 allopurinol‐hypersensitivity reactions (including 18 severe cutaneous adverse drug reactions), and only one patient developed febuxostat‐maculopapular exanthema. Moreover, febuxostat did not statistically increase the risk of CVD (hazard ratio (HR), 1.16; P = 0.152) and related death (HR, 1.49; P = 0.496) compared to allopurinol. The result of the meta‐analysis also showed a consistent result. In conclusion, the incidence and severity of febuxostat‐hypersensitivity are lower than with allopurinol. Febuxostat did not show an increased risk of CVD and related death.Keywords
Funding Information
- Ministry of Science and Technology, Taiwan (MOST‐104‐2314‐B‐182A‐148‐MY3, MOST‐104‐2325‐B‐182A‐006, MOST‐105‐2325‐B‐182A‐007, MOST‐106‐2314‐B‐182A‐037‐MY3, MOST‐106‐2622‐B‐182A‐003‐CC2, MOST‐107‐2622‐B‐182A‐001‐CC2)
- Chang Gung Memorial Hospital, Linkou (CIRPD1D0031, CLRPG2E0053, CMRPG3D0363, CORPG3F0042~3, OMRPG3E0041, CIRPD1D0032)
- Chang Gung Memorial Hospital (CMRPG2H0081)
- Astellas Pharma
This publication has 42 references indexed in Scilit:
- 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaArthritis Care & Research, 2012
- Association of HLA-B*5801 allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysisBMC Medical Genetics, 2011
- Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in KoreansPharmacogenetics and Genomics, 2011
- Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysisBMJ, 2011
- The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trialArthritis Research & Therapy, 2010
- Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai populationPharmacogenetics and Genomics, 2009
- Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and IsraelJournal of the American Academy of Dermatology, 2008
- Allopurinol Dosing in Renal Impairment: Walking the Tightrope Between Adequate Urate Lowering and Adverse EventsSeminars in Dialysis, 2007
- Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and GoutNew England Journal of Medicine, 2005
- Two-sided confidence intervals for the single proportion: comparison of seven methods by Robert G. Newcombe,Statistics in Medicine 1998;17:857–872Statistics in Medicine, 2005